171 related articles for article (PubMed ID: 38012788)
1. Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma.
Tateishi K; Miyake Y; Nakamura T; Iwashita H; Hayashi T; Oshima A; Honma H; Hayashi H; Sugino K; Kato M; Satomi K; Fujii S; Komori T; Yamamoto T; Cahill DP; Wakimoto H
Acta Neuropathol Commun; 2023 Nov; 11(1):186. PubMed ID: 38012788
[TBL] [Abstract][Full Text] [Related]
2. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
[TBL] [Abstract][Full Text] [Related]
3. IDH-mutant astrocytoma with an evolutional progression to CDKN2A/B homozygous deletion and NTRK fusion during recurrence: A case report.
Kirishima M; Akahane T; Higa N; Suzuki S; Ueno S; Yonezawa H; Uchida H; Hanaya R; Yoshimoto K; Shimajiri S; Kitazono I; Tanimoto A
Pathol Res Pract; 2022 Nov; 239():154163. PubMed ID: 36265224
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.
Yokoda RT; Cobb WS; Yong RL; Crary JF; Viapiano MS; Walker JM; Umphlett M; Tsankova NM; Richardson TE
J Neuropathol Exp Neurol; 2023 Sep; 82(10):845-852. PubMed ID: 37550258
[TBL] [Abstract][Full Text] [Related]
5. A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.
Xi S; Huang Q; Zeng J
J Neuropathol Exp Neurol; 2024 Jan; 83(2):125-130. PubMed ID: 38175671
[TBL] [Abstract][Full Text] [Related]
6. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
Ammendola S; Broggi G; Barresi V
Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
[TBL] [Abstract][Full Text] [Related]
7. Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.
Fortin Ensign SP; Jenkins RB; Giannini C; Sarkaria JN; Galanis E; Kizilbash SH
Neuro Oncol; 2023 Jan; 25(1):28-36. PubMed ID: 35973817
[TBL] [Abstract][Full Text] [Related]
8. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
9. Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas.
Marker DF; Pearce TM
Acta Neuropathol Commun; 2020 Oct; 8(1):169. PubMed ID: 33081848
[TBL] [Abstract][Full Text] [Related]
10. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
[TBL] [Abstract][Full Text] [Related]
11. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
12. Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A.
Leske H; Blakstad H; Lund-Iversen M; Skovholt EK; Niehusmann P; Ramm-Pettersen JT; Skogen K; Kongelf G; Sprauten M; Magelssen H; Brandal P
Neuropathology; 2023 Oct; 43(5):385-390. PubMed ID: 36754566
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
Yang RR; Li KK; Zhang ZY; Chan AK; Wang WW; Chan DT; Li WC; Liu XZ; Li FC; Chen H; Ng HK; Mao Y; Shi ZF
Clin Neurol Neurosurg; 2021 Sep; 208():106882. PubMed ID: 34428613
[TBL] [Abstract][Full Text] [Related]
14. IDH-Mutant Astrocytoma With Chromosome 19q13 Deletion Manifesting as an Oligodendroglioma-Like Morphology.
Miyake Y; Fujii K; Nakamaura T; Ikegaya N; Matsushita Y; Gobayashi Y; Iwashita H; Udaka N; Kumagai J; Murata H; Takemoto Y; Yamanaka S; Ichimura K; Tateishi K; Yamamoto T
J Neuropathol Exp Neurol; 2021 Feb; 80(3):247-253. PubMed ID: 33432322
[TBL] [Abstract][Full Text] [Related]
15. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
[TBL] [Abstract][Full Text] [Related]
16. IDH2 and TP53 mutations are correlated with gliomagenesis in a patient with Maffucci syndrome.
Moriya K; Kaneko MK; Liu X; Hosaka M; Fujishima F; Sakuma J; Ogasawara S; Watanabe M; Sasahara Y; Kure S; Kato Y
Cancer Sci; 2014 Mar; 105(3):359-62. PubMed ID: 24344754
[TBL] [Abstract][Full Text] [Related]
17. IDH1 and IDH2 mutations in gliomas.
Yan H; Parsons DW; Jin G; McLendon R; Rasheed BA; Yuan W; Kos I; Batinic-Haberle I; Jones S; Riggins GJ; Friedman H; Friedman A; Reardon D; Herndon J; Kinzler KW; Velculescu VE; Vogelstein B; Bigner DD
N Engl J Med; 2009 Feb; 360(8):765-73. PubMed ID: 19228619
[TBL] [Abstract][Full Text] [Related]
18. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.
Liu XY; Gerges N; Korshunov A; Sabha N; Khuong-Quang DA; Fontebasso AM; Fleming A; Hadjadj D; Schwartzentruber J; Majewski J; Dong Z; Siegel P; Albrecht S; Croul S; Jones DT; Kool M; Tonjes M; Reifenberger G; Faury D; Zadeh G; Pfister S; Jabado N
Acta Neuropathol; 2012 Nov; 124(5):615-25. PubMed ID: 22886134
[TBL] [Abstract][Full Text] [Related]
19. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
20. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma.
Phillips JJ; Aranda D; Ellison DW; Judkins AR; Croul SE; Brat DJ; Ligon KL; Horbinski C; Venneti S; Zadeh G; Santi M; Zhou S; Appin CL; Sioletic S; Sullivan LM; Martinez-Lage M; Robinson AE; Yong WH; Cloughesy T; Lai A; Phillips HS; Marshall R; Mueller S; Haas-Kogan DA; Molinaro AM; Perry A
Brain Pathol; 2013 Sep; 23(5):565-73. PubMed ID: 23438035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]